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Introduction
Hypercholesterolaemia is a risk factor of cardiovascular diseases
and is therefore a major target for primary and secondary preven-
tion.
1,2 Maintaining a healthy diet and lifestyle reduces cardiovascu-
lar risk.
3 ‘Functional foods’ supplemented with phytosterols are
advertised for the management of hypercholesterolaemia and
have become a widely used non-prescription approach to lower
plasma cholesterol levels. It is estimated that in 2005 worldwide
3 billion US-dollars were spent on various functional foods that
have regulator-approved health claims for the management of
elevated cholesterol levels.
4
In September 2000, the US Food and Drug Administration (FDA)
issued an interim ﬁnal rule allowing a health claim for reducing
the risk of coronary heart disease for foods that contain phytos-
terols and are low in saturated fat and cholesterol.
5 In fact, this
was only the 12th time the FDA has authorized a health claim.
The National Cholesterol Education Program Expert Panel (NCEP
ATP III) recommends since 2001 phytosterol enriched functional
foods as part of an optimal dietetic prevention strategy in
primary and secondary prevention of cardiovascular diseases.
6
The American Heart Association (AHA) has followed and sees
phytosterols ‘as a therapeutic option ...for individuals with elev-
ated cholesterol levels’.
3 Since then other well-esteemed societies
such as the Spanish Cardiology Society,
7 the Association of Clinical and
Public Health Nutritionists in Finland,
8 and the National Heart Foun-
dation in Australia,
9 to name only a few, have identiﬁed phytosterols
as an important additional dietary option in the management of
hypercholesterolaemia. However, recently released guidelines are
more critical of food supplementation with phytosterols and
draw attention to signiﬁcant safety issues.
10,11
Phytosterols and cholesterol
absorption
‘Phytosterols’ are natural constituents of plants and are part of the
broad group of isoprenoides. In plant cells, they contribute to the
regulation of the ﬂuidity and permeability of cell membranes, are
substrates for the synthesis of numerous secondary plant metab-
olites and act as biogenic precursors of compounds involved in
growth.
12 Phytosterols are structurally related to cholesterol.
They are non-nutritive compounds whose chemical structure
differs from that of cholesterol only by minor modiﬁcations. Sitos-
terol and campesterol are the most frequent plant sterols and con-
stitute about 60% and 35%, respectively, of plant sterols in food.
They differ from cholesterol in the structure of their side chain
by a methyl or ethyl group at C-24. Plant stanols, on the other
hand, are the saturated form of plant sterols, meaning they have
no double bond in the sterol ring. Saturation of sitosterol, the
most commonly occurring plant sterol, gives rise to sitostanol; sat-
uration of campesterol gives rise to campestanol. See also Figure 1.
Estimates for intestinal absorption range from 0.4 to 5% for plant
sterols and from 0.02 to 0.3% for their saturated counterparts.
13,14
Consequently, plant stanol concentrations in serum are much
lower than plant sterol concentrations. Phytosterols are abundant
in fat-laden vegetables and vegetable products, such as vegetables
oils and olive oil, but also in fruits and nuts. Although cholesterol
and phytosterols are structurally similar, they are metabolized dif-
ferently. In contrast to cholesterol, phytosterols are not syn-
thesized in the body and are solely of dietary origin. The normal
Western-type diet contains about 200–500 mg cholesterol,
200–400 mg plant sterols, and about 50 mg of plant stanols. In
order to be absorbed, cholesterol and phytosterols are taken up
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layer, enabling absorption in entrocytes. Phytosterols competitively
inhibit intestinal absorption of cholesterol. The exact molecular
mechanisms involved are not completely understood; however, it
is clear that both cholesterol and phytosterols require the
Niemann-Pick C1 Like 1 protein (NCP1L1) to obtain entry in
enterocytes. In enterocytes, cholesterol is esteriﬁed via the
enzyme acetyl-coenzyme A acetyltransferase 2 (ACAT2), packed
into chylomycrons, and drained into the lymph system via the
basolateral membrane. Non-esteriﬁed cholesterol and phytoster-
ols are pumped back into the intestinal lumen via the ATP proteins
ABCG5 and ABCG8. These complex mechanisms are responsible
for the assimilation of about 50% of cholesterol, but less than 5% of
plant sterols and even less than 0.5% of plant stanols. The major
part of assimilated phytosterols is directly eliminated via the liver
and the biliary system so that, in the end in healthy individuals,
less than 1% is retained.
15
Phytosterols in nutraceuticals
The plant sterol sitosterol was ﬁrst described as a therapeutic
agent for hypercholesterolaemia in 1951.
16 In the late 1950s, Eli
Lilly Company introduced the ﬁrst plant sterol product, ‘Cytellin’,
as a cholesterol-lowering pharmaceutical.
17 Due to its low water
solubility and the resulting low bioavailability, a daily intake of
18 g of sitosterol was needed to achieve a reduction in serum
cholesterol levels. The product was unmarketable as a pharma-
ceutical agent and production was stopped. A resurgence of inter-
est in phytosterol effects came after it could be demonstrated that
phytosterols were active when incorporated into the diet as
spreads. In the beginning of the 90s, researchers succeeded by
the esteriﬁcation of phytosterols in developing a process which
considerably improved the water solubility of phytosterols.
18
This process made it possible to greatly expand the market for
phytosterols as dietary supplements, leading to a rapidly growing
world-wide market for functional-foods.
19,20 At present in the
EU, in addition to spreads, there are numerous other foods
approved for the market to which phytosterols have been
added, for example, salad dressing; milk, soy, yoghurt, cheesy pro-
ducts; soy and fruit drinks, even sausages and breads. Above all,
combined consumption of these new types of products can lead
to a cumulative intake of very high concentrations especially of
plant sterols, which can affect the absorption of cartenoids and
fat-soluble vitamin.
21 This can, for example, constitute a hazard
to children, pregnant and breastfeeding women. A labelling,
therefore, advises these individuals to avoid consuming these
products. Furthermore, it has been suggested as a precaution
that phytosterol intake should not exceed 3 g per day.
22
Phytosterols and cardiovascular
risk
Meta-analyses of more than 40 clinical studies indicate that phytos-
terols taken as dietary supplements can induce a reduction of
LDL-cholesterol up to 15%
23,24 (Figure 2). However, ingestion of
Figure 1 Chemical structure of cholesterol, sitosterol (plant
sterol), and sitostanol (plant stanol). Both plant sterols and plant
stanols differ from cholesterol only in the side chain attached to
the sterol ring. Plant stanols are saturated plant sterols without a
double bond in the sterol ring. Due to their saturation status,
plant stanols are less effectively absorbed. Esteriﬁed plant sterols
and plant stanols are supplemented in ‘nutraceuticals’ to reduce
serum cholesterol levels (modiﬁed from ref. 14).
Figure 2 Plant sterols reduce serum cholesterol levels. Total cholesterol and LDL-cholesterol dependent on diet (modiﬁed from ref. 23).
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terol levels. Of note, a diet supplementation with plant stanol
esters reduces not only serum cholesterol levels, but also serum
plant sterol concentrations.
25 The effectiveness of cholesterol-
lowering products does not only depend on the amount of
dietary phytosterols, but also on genetically determined differences
in sterol metabolism. Thus, for example, Apo E-4 (apolipoprotein
E-4) homozygote patients on a diet supplementation with phytos-
terols show a more signiﬁcant reduction in LDL-cholesterol due to
their increased cholesterol absorption capacity.
26 However, with
this genotype lowered cholesterol levels are associated with mark-
edly increased plant sterol serum concentrations. The signiﬁcance
of increased plant sterol levels, however, is not clear.
Speculations that plant sterols may represent a cardiovascular
risk factor were ﬁrst brought up after the understanding of the
autosomal-recessively inherited disease of sitosterolaemia.
27 Elev-
ated plant sterol concentrations, xanthomatosis, and premature,
frequently lethal atherosclerosis in young subjects are the most
striking features regarding patients with homozygous sitostero-
laemia. Additional ﬁndings are thrombocytopenia, abnormally
deformed erythrocytes with membranous incorporation of phy-
tosterols, extending to haemolytic crisis, arthralgias, and increased
liver enzyme levels. The reason for this are mutations of the gene
locus of the ABCG5 and ABCG8 co-transporters, resulting in
increased absorption and reduced biliary elimination of all
sterols.
28 In contrast to healthy subjects who have a plant sterol
plasma concentration lower than 1 mg/dL, patients who suffer
from this rare autosomal-recessive, inherited disease, have
plasma concentrations of between 12 and 50 mg/dL. On the
other hand, cholesterol does not need to be excessively high.
The fact that patients with this disease present with an aggressive
vascular disease process despite nearly normal cholesterol levels
brought up the question whether phytosterols have a particularly
atherogenous potential. As sterol analyses of xanthomas of such
patients indicate that phytosterols only contain a small portion
of sterols and that the major portion consists of free and esteriﬁed
cholesterol, it is currently suggested that plant sterols can promote
the incorporation of cholesterol in tissue.
27–29 This speculation is
in agreement with the ﬁndings of a recently published study in
which the NPC1L1 inhibitor ezetimibe led to a regression in
xanthomatosis in parallel to lowering of both cholesterol and
plant sterol levels.
30
Even though many different clinical trials have clearly demon-
strated that phytosterols reduce LDL-cholesterol, it is unclear
whether phytosterols have a positive effect on cardiovascular
disease.
24 Until now, there are no data on the effect of phytosterol
consumption on the development of cardiovascular diseases avail-
able.
32 In fact, there is evidence that elevated levels of plant sterols
are associated with an increased cardiovascular risk. Glueck et al.
33
were the ﬁrst to report that elevated plant sterols might be a risk
factor for coronary heart disease. In a study with 595 hyper-
cholesterolaemic patients, they found that slightly elevated
plasma levels of plant sterols were a heritable marker for an
increased cardiovascular risk. Salen et al.
31 reported that in
homozygotes of sitosterolaemia cholesterol accounted for over
80% of plasma, tissue, and atheroma sterol. In seven subjects in a
Glueck study, serum cholesterol was 7.09 mmol/L, whereas the
concentration of campesterol, stigmasterol, and sitosterol com-
bined was only 43.86 mmol/L.
34 Therefore, it can be speculated
that a slight excess of serum plant sterol levels may increase
sterol deposition in cardiovascular tissue. This hypothesis is sup-
ported by the study of Rajaratnam et al.
35 who found that in post-
menopausal women, plant sterols were independently associated
with coronary heart disease in a multivariate analysis. These ﬁnd-
ings were conﬁrmed by Sutherland and his team in a study invol-
ving both sexes over all age groups.
36 Sudhop et al.
37 analysed
the relation of a positive family history of coronary heart disease
to serum plant sterol concentrations in CAD patients without
lipid-modifying medications. There were no differences in levels
of serum cholesterol, cholesterol precursors, and lipoproteins.
The serum campesterol level in the control group was 0.38 mg/
dL compared to 0.50 mg/dL in those patients with a positive
family history. Given that the level of plant sterols was small com-
pared with cholesterol (0.16 vs. 0.21%), the effect inducing a nega-
tive cardiovascular outcome in this study is indeed very potent.
Similar ﬁndings have been reported for patients on statin treat-
ment. The Scandinavian Simvastatin Survey Study (4S study) also
identiﬁed a subpopulation of coronary artery disease patients
with low endogenous synthesis of cholesterol and high absorption
of cholesterol and plant sterols. The subjects of this subpopulation
had the highest levels of plant sterols and the highest risk of recur-
rent coronary events despite lower levels of serum cholesterol due
to simvastatin ingestion.
38 Larger epidemiological studies reported
similar data. Results of the PROCAM-study showed that patients
afﬂicted with myocardial infarction or sudden cardiac death had
increased plant sterol concentrations.
39 Upper normal levels of
plant sterols were associated with a three-fold increase of risk
for coronary events among men in the highest tertile of coronary
risk according to the PROCAM-algorithm (Figure 3). Similar data are
available for the plant sterol campesterol from the MONICA/
KORA-study. In this prospective study, campesterol correlated
directly with the incidence of acute myocardial infarction.
40
Figure 3 Plant sterols increase cardiac risk. PROCAM-score
for the 10 year risk to develop coronary heart disease
(n ¼ 477) according to subgroups with increasing risk
(PROCAM-score ,10, 10–20, .20). Slightly elevated sitosterol
levels are associated with increased cardiac risk. *P , 0.05 low
sitosterol (,0.21 mg/dL) vs. elevated sitosterol (.0.21 mg/dL)
(modiﬁed from ref. 39).
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show that a diet supplementation with plant sterol esters that is
equivalent to a commercially available spread induces endothelial
dysfunction and leads to an increase of ischaemic stroke size in
wild-type mice.
29 In atherosclerotic-prone apoE2/2 mice, we
compared the effects of a diet supplementation with plant sterol
esters with equal cholesterol lowering by a second intervention
in relation to atherosclerotic lesion formation. Ezetimibe was
chosen as a comparator, because similar to plant sterols, this
two-azetidione is an inhibitor of intestinal cholesterol absorption
and lowers plasma cholesterol levels. As expected, the substantial
lipid-lowering by both treatment principles reduced atherosclero-
tic lesion formation. However, despite equal plasma cholesterol
levels, plant sterol ester supplementation was associated with
twice the amount of plaque formation compared with ezetimibe.
Thus, we found a positive correlation between sterol concen-
trations and the extent of atherosclerotic lesions.
29 Moreover, in
a clinical study, we demonstrated that patients who were
consuming plant sterol ester enriched margarine had increased
concentrations of plant sterols in cardiovascular tissue.
29 Further
mechanistic data suggest that vascular deposits of sterols, when
compared with cholesterol, result in increased oxidation and
release of oxygen radicals.
41 On the other hand, previous animal
and in vitro experiments have shown that plant sterols have
positive effects that directly inhibit tumour growth, including the
slowing of cell cycle progression, the induction of apoptosis, and
the inhibition of tumour metastasis, suggesting that these
compounds have anticancer properties.
42 However, the induction
of apoptosis is not limited to tumour cells, but extends also to
vascular cells. Recent in vitro experiments demonstrated that the
plant sterol sitosterol exerts a strong cytotoxic propensity inducing
apoptosis in human endothelial cells, revealing detrimental effects
on the vasculature.
43 In fact, the ﬁrst experimental study reporting
negative cardiovascular effects dates back to the year 2000.
Ratnayake et al.
44 reported that increased serum levels of plant
sterols increase rigidity of erythrocytes and shorten the life span
of stroke-prone spontaneously hypertensive (SHRSP) rats. These
ﬁndings were the reason for Health Canada, the federal department
responsible for helping Canadians maintain and improve their
health, to raise signiﬁcant safety issues and not to allow
functional foods enriched with plant sterol esters to be sold in
Canada.
45
Phytosterols as adjunct to
over-the-counter drugs
Just recently, a plant sterol–aspirin combination product has
been launched in the USA, despite the fact that the FDA has
written warnings to companies marketing the combination of
drugs with dietary supplements in the past.
46,47 This ‘analgetic
phytosterol supplement’ combines 81 mg aspirin and 400 mg of
plant sterols and carries both over-the-counter (OTC) drug
and dietary supplement labelling and claims. The American
Herbal Products Association (AHPA), however, took issue with
this kind of marketing because it implied both active ingredients
have been submitted to pharma-level testing when in fact only
the OTC drug ingredients had been tested. According to the
AHPA, this would be potentially deceptive for consumers
and would constitute a change in FDA policies. At present,
this issue highlights a legal grey area that requires further
reﬁnement.
48
Do current guidelines for
therapeutic lifestyle changes have
to be reconsidered?
Since the introduction on the market of the ﬁrst phytosterol
enriched margarine, no cases with negative health effects have
been reported. However, controlled studies are only available
for an observational period of up to 1 year, for which the
number of participants was low and the special effects of plant
sterols were not studied separately, so that the possible
pro-atherosclerotic effects due to long-term consumption could
not be detected in these studies.
19,20,23,24,49 In contrast to func-
tional foods enriched with saturated, less absorbable plant stanol
esters (which reduce not only serum cholesterol, but also plant
sterol levels), a diet supplementation with plant sterol esters has
proven to lead to a signiﬁcant increase in plant sterol levels.
20,50
Functional foods are marketed directly to consumers. In com-
parison to drugs, food supplements are subject to much ‘weaker’
authorization and control requirements, but this does not
exclude the possibility that they might be hazardous.
Due to the lack of evidence regarding clinical events and the
potential for negative side-effects, the ‘health claim’ of the US
Food and Drug Administration, the NCEP ATP III guidelines, and
the current diet and lifestyle recommendations of the American
Heart Association should be re-evaluated. The German Drug
Commission (Arzneimittelkommission der Deutschen A ¨rzteschaft)
has stated in January 2004 that because of unclear safety data and
lacking evidence of effectiveness, the general use of such products
was not to be recommended.
10 Similarly, the recently revised
guidelines for primary and secondary prevention of cardiovascular
diseases of the National Health System (NHS) call for randomized
controlled trials testing relevant clinical endpoints.
11 As long as
results of such trials are pending, recommendation of functional
foods or drugs supplemented with plant sterol esters to reduce
serum cholesterol concentrations will be a matter of controversial
debate.
Summary points
Currently there are no data available indicating that functional
foods supplemented with plant sterol esters reduce cardiovascular
events.
Findings in patients with the hereditary disease of sitosterolae-
mia, data from epidemiological studies, as well as recently pub-
lished in vitro and in vivo data suggest that plant sterols potentially
induce negative cardiovascular effects.
Prospective clinical studies testing relevant clinical endpoints are
needed, before a diet supplementation with plant sterol esters can
be recommended.
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Extrinsic compression of the right coronary artery
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A 59-year-old woman was admitted to our
department for cardiac catheterization due
to aortic stenosis and atypical for angina
symptoms. She had her mitral valve replaced
in 1993 with a mechanical bileaﬂet St Jude
valve, due to severe mitral stenosis. She was
also in chronic atrial ﬁbrillation and was
takingoralanticoagulants.Theelectrocardio-
gram showed atrial ﬁbrillation and ST
depression in leads I, II, III, aVF, and V3–V6.
Transthoracic and transoesophageal echo-
cardiogram showed that the mechanical
mitralvalvewasfunctioningwell.Theleftven-
tricle dimensions were within normal limits
and the systolic function was also normal.
However, moderate to severe aortic valve
stenosisandmoderatetosevereaorticregur-
gitationwerenoted.Therightventriclesysto-
lic pressure (RVSP) was 30 mmHg.
The left ventriculography revealed very
good systolic performance of the left ventri-
cle. No mitral regurgitation was noted and
the systolic pull-back gradient across the
aortic valve was 50 mmHg. The aortogram
showed normal dimensions of ascending
aorta and moderate to severe aortic regurgi-
tation. The left coronary arteries were free of intraluminal disease and the right coronary artery (RCA) was a large dominant artery.
However a signiﬁcant focal stenosis in RCA was noted proximally due to extrinsic compression caused by a large surgical sternal met-
allic suture, used during the previous cardiac surgery.
The focal stenosis caused by the metallic suture was probably causing the atypical for angina symptoms. The RCA was not throm-
bosed throughout the years, probably because of the anticoagulation treatment that the patient is receiving for the mechanical mitral
valve and the chronic AF. The patient was referred to the cardiac surgeons for removal of the metallic suture and aortic valve
replacement.
See online supplementary movie available at European Heart Journal online.
Panel A.L A O4 5 8, CRA 08 view of the RCA.
Panel B.L A O0 8, CRA 208 view of the RCA.
Panel C.L A O9 0 8, CRA 08 view of the RCA.
Panel D. Aortogram in LAO 458, CRA 08 view.
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